

Epidemiology

Prevalence: 30-45 % in the population (~1.28 billion patients)


35 % in the Hungarian adult population


$2.5\ \%$ in the Hungarian adolescent population


Significance:


- +1 mmHg increase of BP \rightarrow +1.5% excess in cardiovascular mortality.
- HT causes 58% of coronary heart disease, and 75-90% of stroke.
- Effective HT treatment can reduce cardiovascular mortality by 21%
- Lowering systolic blood pressure (SBP) by 10 mmHg would reduce the relative risk of stroke by 30%.


4

























Prev	alence o	f risk fac	tors
Age		Obesity	Diabetes
Genetic factors			Others
Diabetic patients have	e twice the prevalence	of HT.	


Pre	valenc	e of r	isk fact	ors
Age	Gender		Obesity	Diabetes
	Geograpi	Socio	demographie	
	Cai	rdiovascular r		
Risk factors (RF), asymptomatic organ damage	High normal 130-139 / 85-89	Grade 1 HT 140-159 / 90-9		Grade 3 HT 9 ≥180/≥110
No other RF	Low (<1%)	Low	Moderate (1-5%	High
1-2 RF	Low	Moderate	Moderate - High	High
≥ 3 RF	Low - Moderate	Moderate - Hig	h High	High
Organ damage, CKD stage 3 or diabetes	Moderate - High	High (5-10%)	High	High - Very high
Symptomatic CVD, CKD stage ≥4 or diabetes with organ damage	Very high (>10%)	Very high	Very high	Very high
	*The risk of	mortality due to	CV (not just coronary)	diseases over 10 year



















'Frequent'	causes behind secondar	Prevalence in hypertensive patients
Airway cause	Obstructive sleep apnoea	5-10%
Kidney causes	Renal parenchymal disease	2-10%
	Renovascular disease	1-10%
Endocrin causes	Primary hyperaldosteronism	5-15%
	Phaeocromocytoma	<1%
	Chusing's syndrome	<1%
	Hyper- or hypothyroidism	1-2%
	Hyperparathyroidism	<1%
Medication/ substance	oral contraceptive pill, diet pills, stimulant drugs (amphetamine) etc	
Other causes	Preeclampsia, eclampsia	
	Coarctation of the aorta	
	Increased intracranial pressure	





Secondary hypertension Renal causes: Renoparenchymal (chronic glomerulonephritis, chronic pyelonephritis, etc.) 2-10% of HT patients Pathomechanism: (in addition: peripheral vascular resistance \uparrow , baroreflex activity \downarrow , The number of functioning nephrons \downarrow Na⁺ and water excretion ↓ dyslipidaemia and significant atherosclerosis) · Renovascular 1-10% of HT patients Pathomechanism: Causes: atherosclerosis (2/3), Significant stenosis fibromuscular dysplasia (1/3), other: of the renal artery

aneurysm, etc.

26

Renal blood perfusion↓
↓
RAAS↑

Secondary hypertension Renal causes: Renoparenchymal (chronic glomerulonephritis, chronic pyelonephritis, etc.) 2-10% of HT patients Pathomechanism: (in addition: peripheral vascular resistance \uparrow , baroreflex activity \downarrow , The number of functioning nephrons \downarrow Na⁺ and water excretion ↓ dyslipidaemia and significant atherosclerosis) Renovascular 1-10% of HT patients Pathomechanism: Significant stenosis of the renal artery Renal blood perfusion \downarrow RAAS ↑

Secondary hypertension

Endocrine disorders:

• Primary hyperaldosteronism

5-15% of HT patients Causes:

bilateral adrenal hyperplasia (60%) unilateral adrenal adenoma (35%)

• Cushing's syndrome/disease <1% of HT patients

Causes:
Renal mineralocorticoid receptors are sensitive to glucocorticoids.

• Hypo/hyperthyroidism Complex pathomechanism:

TPR ↑ (hypothyroidism)

Increased protein synthesis (hyperthyroidism)


· Pheochromocytoma


Prevalence: 0.05-0.1%

Causes:

Hormon producing adenomas/adrenocortical cancer epinephrine \u00e7, norepinephrine \u00f3,


28





Measurement of blood pressure Cuff size: too tight or too short cuff +20-30 mmHg 10 cm 4 x 8 cm Newborn size 6 x 12 cm Infant size 15 cm 22 cm 9 x 18 cm Child size 12 x 22 cm Small adult size 22-26 cm 27-34 cm 16 x 30 cm Regular adult size Large adult size 35-44 cm 16 x 36 cm 45-52 cm 16 x 42 cm Adult thigh size

31



32

Measurement of blood pressure

- Measurement conditions:

 Ø coffein, Ø alcohol, Ø smoking 30 minutes before the measurement!
- Patient should be seated and relaxed at least 5 minutes before reading and during the procedure! (room temperature, quiet, empty bladder)!
- Both patient and examiner should refrain from talking during the measurement!
- Patient should be seated with legs uncrossed!
 - Crossing the legs increases systolic BP with +2-6 mmHg.
- Patient should be seated with back supported, muscles relaxed!
 - The lack of back support results in a +6 mmHg increase in diastolic blood pressure.
- The lower arm should be level with the heart supported on a pillow, slightly flexed
- Each 2.5 cm difference between heart level and site of measurement results in a 2 $\,$ mmHg deviation.
- At least 2-3 readings should be taken, with a 1-2-minute intervals and take the average of multiple readings!
- In immobilized patients diastolic BP may be lower with 5 mmHg.

Recommendation Reach or maintain normal BMI (<25kg/m²) Reduced sodium intake	Effect of treatment on systolic BP - 5-20 mmHg / 10 kg weight loss
Reach or maintain normal BMI (<25kg/m²) Reduced sodium intake	systolic BP - 5-20 mmHg / 10 kg weight loss
(<25kg/m²) Reduced sodium intake	loss
<5 g/day	- 2-8 mmHg
Legume, fruits, low fat diary oducts, decreased consumption of saturated fatty acids, increased intake of K ⁺ , Ca ²⁺	- 8-10 mmHg
Regular physical activity (30-60 min/day) every day	- 4-9 mmHg
Maximum 2 beverages/day/man (25g alcohol), or 1 beverages/day/woman (12.5g	- 2-10 mmHg
	(30-60 min/day) every day Maximum 2 beverages/day/man (25g alcohol), or 1

Treatment of hypertension Antihypertensive medications Clinical feature Recommended antihypertensive drug Target organ damage Left ventricular hypertrophy $\boldsymbol{ACE\text{-}inhibitor}/\boldsymbol{ARB}, calcium\text{-}antagonist, diuretics}$ Calcium-antagonist, ACE-inhibitor/ARB Asymptomatic atherosclerosis Microalbuminuria ACE-inhibitor/ARB Stroke/TIA Any antihypertensive drugs After myocardial infarction β-blocker, ACE-inhibitor/ARB $\label{eq:ACE-inhibitor} ARB, \beta \text{-blocker}, \text{ aldosterone antagonist}, \text{non dihidropiridin calcium-antagonist}$ Atrial fibrillation Aorta aneurism $\beta\text{-blocker},$ non dihidropiridin calcium-antagonist Diabetes mellitus $\label{eq:ACE-inhibitor/ARB} ACE-inhibitor/ARB, calcium-antagonist, diuretics, imidazolin-receptor-antagonist$ Other conditions Isolated systolic hypertension Diuretics, calcium-antagonist

